Myeloma Matters: Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma

Project Oncology®

Контент предоставлен ReachMD. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией ReachMD или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.

3M ago

MP3•Главная эпизода

Host: Jesus G. Berdeja, MD
Guest: Nicholas G. Barkemeyer, MPAS
Guest: Ajai Chari, MD
Guest: Harvey Church
Guest: Amy Gebhardt
Guest: Steven Morrow
Release date: 7/18/2024
Expiration date: 7/18/2025
Estimated time to complete: 1.0 hour

This activity is not accredited for CME/CE credit.

This episode of Myeloma Matters features discussions of bispecific antibody therapy, a powerful form of targeted immunotherapy that has produced high response rates and helped patients—even those with multiply relapsed or refractory multiple myeloma (RRMM)—achieve deeper and more sustained responses. This podcast will also review strategies for preventing and managing the serious, potentially life-threatening, adverse events (AEs) associated with myeloma bispecific antibody therapy, which include cytokine release syndrome (CRS), neurotoxicity, and infection.

156 эпизодов

#Oncology #Obstetrics And Gynecology #Oncology And Hematology #Omnia Education #Cme/ce #Oncology Power Hour #ReachMD #Women's Health #Women's Health Fridays™ #Science #Medicine #Health and Well-Being #Project Oncology®